Xlife Sciences AG
Develops and commercializes early-stage life sciences research projects.
XLS | SW
Overview
Corporate Details
- ISIN(s):
- CH0461929603 (+1 more)
- LEI:
- 984500AH590BE88BB517
- Country:
- Switzerland
- Address:
- Talacker 35, 8001 Zürich
Description
Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2024-12-19 07:00 |
Xlife Sciences AG Publishes 2023 ESG Report: A Continued Commitment to Sustaina…
|
English | HTML • 12.7 KB | ||
| 2024-12-19 01:00 |
Xlife Sciences AG Publishes 2023 ESG Report: A Continued Commitment to Sustaina…
|
English | HTML • 10.7 KB | ||
| 2024-12-19 01:00 |
Xlife Sciences AG veröffentlicht ESG-Bericht 2023: Ein kontinuierliches Engagem…
|
German | HTML • 11.1 KB | ||
| 2024-12-17 07:00 |
Xlife Sciences AG Announces the Intended Listing of VERAXA Biotech AG on the NA…
|
English | HTML • 8.1 KB | ||
| 2024-12-16 07:00 |
Xlife Sciences AG Announces the Intended Listing of VERAXA Biotech AG on the NA…
|
English | HTML • 8.1 KB | ||
| 2024-12-16 01:00 |
Xlife Sciences AG Announces the Intended Listing of VERAXA Biotech AG on the NA…
|
English | HTML • 6.5 KB | ||
| 2024-12-16 01:00 |
Xlife Sciences AG kündigt geplanten Börsengang der VERAXA Biotech AG an der US-…
|
German | HTML • 10.3 KB | ||
| 2024-11-22 07:00 |
Xlife Sciences AG Announces the listing of FUSE-AI GmbH on the London Stock Exc…
|
English | HTML • 7.8 KB | ||
| 2024-11-21 07:00 |
Xlife Sciences AG Announces the listing of FUSE-AI GmbH on the London Stock Exc…
|
English | HTML • 7.8 KB | ||
| 2024-11-21 01:00 |
Xlife Sciences AG Announces the listing of FUSE-AI GmbH on the London Stock Exc…
|
English | HTML • 6.3 KB | ||
| 2024-11-21 01:00 |
Xlife Sciences AG kündigt Börsengang der FUSE-AI GmbH an der Londoner Börse im …
|
German | HTML • 9.5 KB | ||
| 2024-09-30 20:00 |
Xlife Sciences AG enables international co-investors to enter the stock and is …
|
English | HTML • 7.0 KB | ||
| 2024-09-30 02:00 |
Xlife Sciences AG enables international co-investors to enter the stock and is …
|
English | HTML • 5.4 KB | ||
| 2024-09-30 02:00 |
Xlife Sciences AG ermöglicht internationalen Co-Investoren den Einstieg in die …
|
German | HTML • 7.6 KB | ||
| 2024-09-19 02:00 |
Xlife Sciences AG: Successful First Half of 2024 with Strategic Progress and So…
|
English | HTML • 8.4 KB |
Automate Your Workflow. Get a real-time feed of all Xlife Sciences AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xlife Sciences AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xlife Sciences AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-15 | N/A | Executive member | Buy | None | 6,000.00 CHF |
| 2022-06-15 | N/A | Executive member | Buy | None | 3,000.00 CHF |
| 2022-06-14 | N/A | Executive member | Buy | None | 15,500.00 CHF |
| 2022-06-10 | N/A | Executive member | Buy | None | 6,728.90 CHF |
| 2022-06-07 | N/A | Executive member | Buy | None | 34,800.00 CHF |
| 2022-06-03 | N/A | Executive member | Buy | None | 3,540.00 CHF |
| 2022-05-24 | N/A | Executive member | Buy | None | 3,400.00 CHF |
| 2022-05-17 | N/A | Executive member | Buy | None | 10,794.20 CHF |
| 2022-05-13 | N/A | Executive member | Buy | None | 3,690.00 CHF |
| 2022-05-10 | N/A | Executive member | Buy | None | 1,935.00 CHF |
Peer Companies
